Overview
Status
Active
Registry date
2023-09-04
Share capital
5 000,00 PLN
Registered address
ul. Wiertnicza 115, 02-952 Warszawa, Poland
Electronic delivery address
AE:PL-30320-37716-TVUES-30
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 1.49mMedianUSD 344.81kAverageUSD 8.15m
Net profit
This companyUSD 282.70kMedianUSD 4.87kAverageUSD 684.24k
Operating costs
This companyUSD 1.14mMedianUSD 396.72kAverageUSD 7.18m
Assets
This companyUSD 1.13mMedianUSD 373.21kAverageUSD 7.89m
Industry
Bank accounts
Registered as a VAT taxpayer on 2023-09-26. Active
21 1600 1055 1734 0153 1000 0003
22 1160 2202 0000 0005 8353 6791
51 1160 2202 0000 0005 8211 3473
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Authorized Representatives
Remigiusz Szewczyk — President of the Management Board
Manner of representation
The company is represented by the President of the Management Board independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Ruslan Hilchenko (50) | 50 | $675.31 | 50% |
Kostiantyn Polozov (48) | 50 | $675.31 | 50% |
Beneficial owners
| Person | Rights |
|---|---|
Ruslan Hilchenko (50) | Shareholder of a limited liability company, 2500.0 PLN |
Kostiantyn Polozov (48) | Shareholder of a limited liability company, 2500.0 PLN |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| ALG Pharmasp. z o.o. | $16,237,368.88 | algpharma.pl | |
| Norsa Pharmasp. z o.o. | $9,111,390.60 | norsapharma.eu | |
| Yangosp. z o.o. | $8,214,312.60 | yango.pl | |
| OnesanoS.A. | $3,063,535.91 | onesano.pl | |
| Iodica Worldsp. z o.o. | $1,668,750.20 | iodica.pl | |
| IOCsp. z o.o. | $878,940.46 | producentsuplementow.pl | |
| Instytut Urządzeń Ekstrakcyjnychsp. z o.o. | $243,885.18 | sfe.com.pl | |
| Betterme.Biosp. z o.o. | $55,901.95 | betterme.bio | |
| Moodarysp. z o.o. | $34,640.14 | ladujemy.pl | |
| TRZY Wymiarysp. z o.o. | $3,985.66 | agencja3.pl |
FAQ
The main business activity of Novel Nutraceuticals focuses on manufacture of food supplements.
The company was registered in the Polish National Court Register (KRS) on September 4, 2023.
The headquarters is located at: ul. Wiertnicza 115, 02-952 Warszawa.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
The company reported a revenue of USD 1,491,278 in 2025, which is an increase of 69.4% compared to 2024.
Yes, in 2025 the company was profitable, achieving a net profit of USD 282,701.
The largest operating cost category falls under cost of goods and materials sold. This category amounted to USD 535,876 in 2025, representing 47% of all operating expenses.
Last updated: 2026-08-28